1Lorber MI, Buren CT, Flechner SM, et al. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation, 1987, 43:35-40.
2Farghali H, Gasbarrini A, Borle AB, et al. FK506 modulates D-galactosamine-induced hepatitis in rats. Transplant Proc, 1991,23: 2809-2811.
3Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol, 1994, 34: 859-864.
4Shapiro R, Scantlebury V, Jordan ML, et al. Posttransplant diabetes in pediatric recipients on tacrolimus. Transplantation, 1999, 67: 771-778.
2Dalinkeviien E,Kuzminskis V,Petrulien K,et al.Ten-year experience of kidney transplantation at the Hospital of Kaunas University of Medicine:demography,complications,graft and patient survival[J].Medicina (Kaunas),2010;46(8):538.
3Lamoureux F,Mestre E,Essig M,et al.Quantitative proteomic analysis of cyclosporine induced toxicity in a human kidney cell line and comparison with tacrolimus[J].J Proteomics,2011,18:274.
4Farghali H,Gasbarrini A,Bode AB,et al.FK506 modulates D galactomine induced hepatitis in ralg[J].Transplant Proc,1991,23:2809.
5Gozdowska J,Urbanowicz AL,Galazka Z,et al.Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients:polish experience[J].Transplant Proc,2011,43(8):2946.
